MVT 5873

Drug Profile

MVT 5873

Alternative Names: 5B1; anti-sialyl Lewisa antibody; HuMab-5B1; MVT-5873

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator MabVax Therapeutics
  • Developer MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center; Sarah Cannon Research Institute
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action GD2 ganglioside modulators; Tumour-associated carbohydrate antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer; Pancreatic cancer
  • Preclinical Small cell lung cancer

Most Recent Events

  • 12 Dec 2016 Phase-I clinical trials in Colorectal (colon) cancer in USA (IV) (MabVax Therapeutics pipeline, December 2016)
  • 05 Dec 2016 Preclinical trials in Colorectal (colon) cancer and Small cell lung cancer in USA (IV) prior to December 2016
  • 28 Nov 2016 Phase-I clinical trials in Pancreatic cancer (Late-stage disease, Metastatic disease, Combination therapy, First-line therapy) in USA (IV) (NCT02672917)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top